Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

A roundup of health news includes Mexico's first screwworm myiasis case, rising measles cases in Texas, the launch of a new ...

People who cannot generate an effective immune response against COVID-19 can be protected with an infusion of Regeneron's antibody therapy REGN-COV, according to new data from the UK RECOVERY trial.

Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the first quarter of 2025. Sales increased 7% year over ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

Regeneron has also been working with partner Sanofi to try to repurpose their anti-IL-6 antibody Kevzara (sarilumab) as a COVID-19 treatment, but that has yielded disappointing results in patients ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...